文献速递淋巴瘤

原发性纵隔大B细胞淋巴瘤的生物学特征与治疗进展

Primary mediastinal large B-cell lymphoma.
PubMed 文献 · Blood · 2022-01-01

原发性纵隔大B细胞淋巴瘤(PMBCL)是WHO分类中独立实体,分子特征与结节硬化型经典霍奇金淋巴瘤重叠。RNA分类器可区分PMBCL与DLBCL,但约5%的DLBCL无纵隔受累却具PMBCL分子表型,临床信息仍关键。利妥昔单抗时代预后改善,但标准治疗和放疗整合存争议,难治性疾病可达10%且预后差,PD1抑制剂前线整合研究进行中。

要点

  • PMBCL是独立实体,分子特征与cHL重叠,JAK-STAT和NF-κB通路重要。
  • 约5%的DLBCL无纵隔受累但有PMBCL分子表型,诊断需结合临床信息。
  • 利妥昔单抗时代预后改善,但标准治疗和放疗整合仍存争议,难治率可达10%。

核心结论

  • PMBCL基于临床病理和独特分子特征为独立实体,与cHL分子重叠,利妥昔单抗时代预后改善但治疗争议尚存。

研究设计与样本

  • 综述性文章,总结PMBCL的生物学特征、诊断分类及治疗研究进展,未报告系统检索范围。

主要发现

  • PMBCL生物学特征与cHL相似,涉及JAK-STAT和NF-κB信号通路及免疫逃逸表型。
  • RNA分类器可区分PMBCL与DLBCL,但约5%的DLBCL无纵隔受累却具PMBCL分子表型。
  • 利妥昔单抗时代PMBCL预后改善,但难治性疾病可达10%且与不良预后相关。
  • PD1抑制剂在PMBCL中显示高效,前线整合研究正在进行。

临床怎么用

  • 诊断PMBCL需结合临床信息,因约5%的DLBCL无纵隔受累却具PMBCL分子表型。
  • 治疗选择需考虑利妥昔单抗时代背景,放疗整合时机尚存争议。
  • 难治性疾病可达10%,需关注预后不良患者,PD1抑制剂前线整合研究值得关注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary mediastinal large B-cell lymphoma (PMBCL) is a separate entity in the World Health Organization's classification, based on clinicopathologic features and a distinct molecular signature that overlaps with nodular sclerosis classic Hodgkin lymphoma (cHL). Molecular classifiers can distinguish PMBCL from diffuse large B-cell lymphoma (DLBCL) using ribonucleic acid derived from paraffin-embedded tissue and are integral to future studies. However, given that ∼5% of DLBCL can have a molecular PMBCL phenotype in the absence of mediastinal involvement, clinical information remains critical for diagnosis. Studies during the past 10 to 20 years have elucidated the biologic hallmarks of PMBCL that are reminiscent of cHL, including the importance of the JAK-STAT and NF-κB signaling pathways, as well as an immune evasion phenotype through multiple converging genetic aberrations. The outcome of PMBCL has improved in the modern rituximab era; however, whether there is a single standard treatment for all patients and when to integrate radiotherapy remains controversial. Regardless of the frontline therapy, refractory disease can occur in up to 10% of patients and correlates with poor outcome. With emerging data supporting the high efficacy of PD1 inhibitors in PMBCL, studies are underway that integrate them into the up-front setting.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Savage KJ. Primary mediastinal large B-cell lymphoma. Blood. 2022. PMID: 34496020. doi:10.1182/blood.2020008376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。